In this on-demand activity, Jason T. Jacobson, MD, FHRS, of Westchester Med Center-New York Med College, discusses the CAST trial with David J. Callans, MD, FHRS, CCDS of Hospital of the University of Pennsylvania, and Gerald V Naccarelli, MD, FHRS of Pennsylvania State University Milton S. Hershey Medical Center. Class IC antiarrhythmic drugs have been generally avoided in patients with any degree of coronary disease and any type of cardiomyopathy, whether or not they fit the inclusion criteria of the trial. For the past 3+ decades, the CAST trial results have been extrapolated to a broader population despite a lack of evidence. In this study, the authors retrospectively look at the safety of these agents compared with Class III drugs in patients with atrial fibrillation and varying degrees of CAD.
- Provider:Heart Rhythm Society
- Activity Link: https://www.heartrhythm365.org/Users/LearningActivityInformation.aspx?LearningActivityID=98rffQRCyL10MlpKNKJXeQ%3d%3d
- Start Date: 2023-11-07 06:00:00
- End Date: 2023-11-07 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.25 hours
- MOC Credit Details: ABIM - 0.25 Point; Credit Type(s): Medical Knowledge (ABIM)
ABP - 0.25 Point; Credit Type(s): Lifelong Learning and Self-Assessment (ABP) - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Clinical Cardiac Electrophysiology, Pediatric Cardiology